Autolus Therapeutics plc
HealthcareNASDAQ:AUTL · NASDAQ Global Select
+$0.00 today
Vol 1.02M · Avg 1.60M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-161.8%
avg -65.2%
ROIC
-51.5%
avg -46.1%
ROA
-48.9%
avg -34.9%
Analysis
ROA is currently the strongest return metric at -48.9% versus its period average of -34.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christian Martin Itin | Chief Executive Officer & Director | $2.67M | — | 62 | $1.12M | 0.42% |
Chris Williams | Senior VP & Chief Business Development Officer | — | — | 46 | $8,198.00 | <0.01% |
Martin Pule MBBS | Founder, Senior Vice President & Chief Scientific Officer | — | — | 54 | $0.00 | <0.01% |
Matthias Will | Senior Vice President & Chief Development Officer | — | — | 53 | $0.00 | <0.01% |
Alexander Swan | Senior Vice President & Chief Human Resources Officer | — | — | 61 | $0.00 | <0.01% |
Alex Driggs | Senior Vice President of Legal Affairs & General Counsel and Secretary | — | — | 50 | $0.00 | <0.01% |
Christopher Vann | Senior Vice President & Chief Operating Officer | — | — | 61 | $152,211.00 | 0.06% |
Patrick McIlvenny | Senior VP of Finance, Chief Accounting Officer & Principal Accounting Officer | — | — | 46 | $0.00 | <0.01% |
Robert F. Dolski | Senior Vice President & Chief Financial Officer | — | — | 55 | $0.00 | <0.01% |
Miranda Neville | Senior VP & Chief Technology Officer | — | — | 51 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +33.9% | +64.9% (11yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +33.9% over three years. Forward estimates point to Revenue at +64.9% (11yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
Benitec Biopharma Inc.
NASDAQ:BNTC
$293.44M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
Who manages AUTL?
Autolus Therapeutics plc (AUTL) lists 10 active executives. The top listed executive is Christian Martin Itin, Chief Executive Officer & Director.
Are AUTL insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.